- TRADE NAMES: BritLofex (Britannia); Lucemyra (US WorldMeds, LLC)
- INDICATIONS: mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
- CLASS: Adrenergic alpha2-receptor agonist
- HALF-LIFE: ~12 hours
- FDA APPROVAL DATE: 05/16/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Methadone, Naltrexone - PREGNANCY: The safety of lofexidine in pregnant women has not been established.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
